GS-6615: Phase I data

The open-label, U.S. Phase I GS-US-279-0110 trial in 10 LQT3 patients with a QTc interval of >480 milliseconds showed that all single oral doses of 10-60 mg GS-6615 shortened QTc intervals, with maxim...